AstraZeneca PLC (AZN)
NASDAQ: AZN · IEX Real-Time Price · USD
-0.52 (-0.75%)
At close: Apr 12, 2024, 4:00 PM
-0.10 (-0.15%)
Pre-market: Apr 15, 2024, 4:10 AM EDT

Company Description

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines.

The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.

Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease.

The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia.

It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999.

AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

AstraZeneca PLC
AstraZeneca logo
Country United Kingdom
Founded 1992
IPO Date May 12, 1993
Industry Drug Manufacturers - General
Sector Healthcare
Employees 89,900
CEO Pascal Soriot D.V.M., M.B.A.

Contact Details

1 Francis Crick Avenue, Cambridge Biomedical Campus
Cambridge, X0 CB2 0AA
United Kingdom
Phone 011 44 20 7304 5000

Stock Details

Ticker Symbol AZN
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0000901832
CUSIP Number 046353108
ISIN Number US0463531089
SIC Code 2834

Key Executives

Name Position
Pascal Soriot D.V.M., M.B.A. Chief Executive Officer and Executive Director
Dr. Aradhana Sarin M.D. Chief Financial Officer and Executive Director
Pam P. Cheng Executive Vice President of Global opt. and IT, Chief Sust. Officer and Member of External Sust.Adv. Board
Andrew P. Barnett Head of Investor Relations
Jeffrey Pott CHRO, Chief Compliance Officer, General Counsel and Member of External Sustainability Advisory Board
Gonzalo Vina Head of Global Media Relations
Dr. Menelas Nicolas Pangalos Ph.D. Executive Vice-President
Dr. Ruud Dobber Ph.D. Executive Vice-President of BioPharmaceuticals Business Unit
Dr. Susan Mary Galbraith M.D., Ph.D. Executive Vice President of Oncology Research and Development
Leon Wang Executive Vice President of International and China President

Latest SEC Filings

Date Type Title
Apr 11, 2024 6-K Report of foreign issuer
Apr 11, 2024 6-K Report of foreign issuer
Apr 8, 2024 6-K Report of foreign issuer
Apr 5, 2024 6-K Report of foreign issuer
Apr 2, 2024 6-K Report of foreign issuer
Apr 2, 2024 6-K Report of foreign issuer
Apr 2, 2024 6-K Report of foreign issuer
Mar 25, 2024 6-K Report of foreign issuer
Mar 19, 2024 F-3ASR Filing
Mar 19, 2024 6-K Report of foreign issuer